Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04642469
Title Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | CAN | BEL

Additional content available in CKB BOOST